N/A N=449 Transplant Regimen Adherence for Kidney Recipients by Engaging Information Technologies: The TAKE IT Trial
Kidney Transplant
Primary: Rx Pill Count — 0.26; 0.26 Probability of adherence (1/0)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=44 Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Chronic Lymphocytic Leukemia
Primary: Number of Patients With Complete Response (CR) — 11 Participants
Phase 1 N=27 Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer
Ovarian Cancer
Primary: Safety and Tolerability of Fostamatinib — 0; 0; 1 Dose Limiting Toxicities (DLTs)
Phase 2 N=48 Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease
Nonalcoholic Fatty Liver Disease (NAFLD) · Type 2 Diabetes (T2DM)
Primary: Change in Intrahepatic Triglycerides (IHTG) Quantified by Proton Magnetic Resonance and Spectroscopy (¹H-MRS) — -8.7; -3.0 percentage decrease from baseline
N/A N=88 Performance of Masimo MightySat Pulse Oximeter in Differing Levels of Skin Pigmentation
Healthy
Primary: SpO2 Accuracy of the MightySat Pulse Oximeter — 1.30 % of oxygen saturated hemoglobin
N/A N=60 Dailies Total 1 Sphere Contact Lenses
Dry Eye · Contact Lens Complication
Primary: Visual Analog Scale (VAS) Contact Lenses Comfort Scores — 44 Score on a scale — p=<0.001
Phase 3 N=269 Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma
Primary: Progression Free Survival (PFS) Based on Investigator Assessment — 106.9; 15.0 months — p=< 0.0001
N/A N=7,052 Blood Glucose Monitoring in Electronic Health Records
Diabetes Mellitus
Primary: Count of Participants Entering Flowsheet Data During Measurement Period, Extensive Margin — 4; 27; 44; 43 Participants
N/A N=67 A Dietary Intervention Study on the Microbiome in Crohn's Disease Patients
Crohn Disease
Primary: Maintenance of Symptomatic Remission, Without Worsening of Any Existing Disease Activity During Study Period — -31.63; -27.57 score on a scale — p=0.469
Phase 1 N=225 A Phase 1 Study of LY2835219 In Participants With Advanced Cancer
Advanced Cancer
Primary: Number of Participants With Clinically Significant Effects — 0; 0; 0; 0 Participants
Phase 2 N=9 Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer
Thyroid Cancer · Anaplastic Thyroid Cancer · Undifferentiated Thyroid Cancer
Primary: Number of Participants With Overall Response (OR) — 0 Participants
N/A N=3 Calcium and Phosphorus Whole-Body Balance and Kinetics in Patients With Moderate Chronic Kidney Disease
Phosphorus and Calcium Disorders · Chronic Kidney Disease Mineral and Bone Disorder · Chronic Kidney Diseases
Primary: Fractional Calcium Absorption — 0.30; 0.42 fraction of 1.00
N/A N=13 Examining the Effect of EEG-guided Theta Burst Stimulation in Bipolar Disorder
Bipolar Disorder
Primary: Brain Activity (Beta Power) in Left vLPFC — -88.78; 1437.64; 13.43; -128.00 Percentage of change post versus pre — p=0.29389090
N/A N=60 Comparing Brief Relaxation Period to Virtual Reality Period in Reducing Dental Anxiety Prior to Root Canal Treatment
Dental Anxiety
Primary: State-Trait Anxiety Inventory State Sub-scale (STAI-S) Score at the End of the Appointment — 27.39; 29.37 units on a scale — p=.399
Phase 2 N=24 Safety and Efficacy of CD10367 in Psoriasis Vulgaris
Psoriasis Vulgaris
Primary: Area Under the Curve (AUC) of Total Sum Score (Sum of Erythema, Scaling and Induration Scores) — 103.4; 101.7; 118.0; 118.6 score on a scale*days